Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy;Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica

Medicina Clinica

Volumn 127, Issue 2, 2006, Pages 41-46

  García Sánchez, María Del Valle ^a   González, Raúl ^a   Iglesias Flores, Eva ^a   Gómez Camacho, Federico ^a   Casais Juanena, Luis ^a   Cerezo Ruiz, Antonio ^a   Montero Pérez Barquero, Manuel ^a   Muntané, Jordi ^a   De Dios Vega, Juan Francisco ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Colonoscopy; Fecal calprotectin; Intestinal inflammation

Indexed keywords

CALPROTECTIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COLON ADENOMA; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ENTERITIS; FECES ANALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PREDICTION; SYMPTOMATOLOGY;

EID: 33746107621     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090002     Document Type: Article

References (28)

1. Thompson WG, Longstreth GF, Drossmann DA, Heaton KW, Irving EJ, Meller-Lissner SA. Funcional bowel disorders and functional abdominal pain. Gut. 1999;45:II453-47.
2. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
3. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leucocyte protein, the LI antigen. Eur J Biochem. 1983;134:1-6.
4. Fagerhol MK, Anderson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the LI leukocyte protein). En: Smith V, Dedman JR, editors. Stimulus response coupling: the role of intracellular calcium-binding proteins. Boca Raton: CRC Press; 1990. p. 187-210.
5. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a market of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:823-5.
6. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. New Eng J Med. 1999;340:448-54.
7. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New Insights into the biology of the acute phase response. J Clin Immunol. 1999;19:203-14.
8. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome Criteria to distinguish organic from nonorganic intestinal disease. Gastroenterol. 2002;123:450-60.
9. Poollis A, Foster R, Northfiled C, Mendal MA. Review: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-81.
10. Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, et al. PMN-elastasa in the assessment of patient with inflammatory bowel disease. Dig Dis Sci. 1993;38:1638-44.
11. Bohe M, Genell S, Ohlsson K. Protease inhibitors in plasma and faecal extracts from patients with activity inflammatory bowel disease. Scand J Gastroenterol. 1986;21:598-604.
12. Brouwer J. Semiquantitative determination of faecal leucocyte esterase by a dip-and-read assay. Clin Chem. 1993;39:2531-2.
13. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparation with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91:927-34.
14. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil domining protein calprotectin in faeces. A methodologic study. Scand J Gastroenterol. 1992;27:793-8.
15. Jhone B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparation with previous method. Scand J Gastroenterol. 2001;36:291-6.
16. Costa F, Mumolo M, Bellini MR, Romano MR, Ceccarelli L, Arpe P, et al. Role of calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-7.
17. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammatory in Crohn's disease. Gut. 2000;47:506-13.
18. Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new market for Crohn's disease? Ann Clin Biochem. 2004;41:230-2.
19. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne B. Diagnostic accuracy of faecal calprotectin estimalatio in predection of abnormal small bowel radiology. Aliment Pharmacol Ther. 2004;20:615-21.
20. Kane S, Sandborn W, Rufo P, Zholudev A, Boone J, Lyerly D, et al. Fecal Lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-14.
21. Kristinsson J, Roseth A, Fagerhol M, Aadland E, Schjonsby H, Bormer O, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum. 1998;41:316-21.
22. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian colorectal cancer prevention trial on flexible sigmoidoscopy screening: comparation with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329-33.
23. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-8.
24. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, et al. Faecal calprotectin in a high risk population for colorectal neoplasia. Gut. 2000;46:795-800.
25. Roseth AG, Kristinsson J, Fagerhol MK. Faecal ccalprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-6.
26. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut. 2001;49:743-5.
27. Poullis A, Foster R, Mendal M. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 203;15:573-4.
28. Tibble JA, Sigthorsson G, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID entropathy as shown by a simple faecal test. Gut. 1999;45:362-6.